Antihistamines and birth defects: A systematic review of the literature

Expert Opinion on Drug Safety

Volumn 13, Issue 12, 2014, Pages 1667-1698

  Gilboa, Suzanne M ^a   Ailes, Elizabeth C ^a   Rai, Ramona P ^b   Anderson, Jaynia A ^b   Honein, Margaret A ^c  

^a NATIONAL CENTER ON BIRTH DEFECTS AND DEVELOPMENTAL DISABILITIES   (United States)

^b EMORY UNIVERSITY   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antihistamines; Birth defects; Pregnancy; Prenatal exposure

Indexed keywords

ANTIHISTAMINIC AGENT; ASTEMIZOLE; BROMPHENIRAMINE; CETIRIZINE; CHLORPHENIRAMINE; CLEMASTINE; CYCLIZINE; DIMENHYDRINATE; DIPHENHYDRAMINE; DIPHENYLPYRALINE; DOXYLAMINE PLUS PYRIDOXINE; FEXOFENADINE; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROXYZINE; IMIPRAMINE; LORATADINE; MECLOZINE; MEPYRAMINE; PROMETHAZINE; PSEUDOEPHEDRINE PLUS TRIPROLIDINE; TERFENADINE; TRIPELENNAMINE; TRIPROLIDINE;

BIRTH DEFECT; FEMALE; HUMAN; HYPOSPADIAS; PREGNANCY OUTCOME; PRENATAL EXPOSURE; PRESCRIPTION; REVIEW; UNITED STATES; CHEMICALLY INDUCED; CONGENITAL ABNORMALITIES; PREGNANCY;

CONGENITAL ABNORMALITIES; FEMALE; HISTAMINE ANTAGONISTS; HUMANS; PREGNANCY; PRENATAL EXPOSURE DELAYED EFFECTS;

EID: 84912036387     PISSN: 14740338     EISSN: 1744764X     Source Type: Journal    
DOI: 10.1517/14740338.2014.970164     Document Type: Review

References (82)

1. Thorpe PG, Gilboa SM, Hernandez-Diaz S, et al. Medications in the first trimester of pregnancy: most common exposures and critical gaps in understanding fetal risk. Pharmacoepidemiol Drug Saf 2013;22:1013-18
2. Werler MM, Mitchell AA, Hernandez-Diaz S, Honein MA. Use of over-The-counter medications during pregnancy. Am J Obstetr Gynecol 2005;193:771-7
3. Gilboa SM, Strickland MJ, Olshan AF, et al. Use of antihistamine medications during early pregnancy and isolated major malformations. Birth Defects Res A Clin Molec Teratol 2009;85:137-50
4. Brent R. Bendectin and birth defects: hopefully, the final chapter. Birth Defects Res A Clin Molec Teratol 2003;67:79-87
5. McKeigue PM, Lamm SH, Linn S, Kutcher JS. Bendectin and birth defects: I. A meta-Analysis of the epidemiologic studies. Teratology 1994;50:27-37
6. Einarson TR, Leeder JS, Koren G. A method for meta-Analysis of epidemiological studies. Drug Intell Clin Pharmacy 1988;22:813-24
7. MacMahon B. More on Bendectin. JAMA 1981;246:371-2
8. Beardsley T. Bendectin/debendox. Drug not guilty, says court. Nature 1985;314:209
9. Brent RL. Bendectin: review of the medical literature of a comprehensively studied human nonteratogen and the most prevalent tortogen-litigen. Reprod Toxicol 1995;9:337-49
10. Danks DM. Blame, compensation and birth defects. Med J Austr 1985;143:135-6
11. Davis JM. Good-bye, Bendectin, old friend. Postgrad Med 1984;75:20-4
12. Källen B. Use of antihistamine drugs in early pregnancy and delivery outcome. J Mat Fet Neonatal Med 2002;11:146-52
13. Asker C, Norstedt Wikner B, Kallen B. Use of antiemetic drugs during pregnancy in Sweden. Eur J Clin Pharmacol 2005;61:899-906
14. Kullander S, Käll-en B. A prospective study of drugs and pregnancy. II. Antiemetic drugs. Acta Obstetr Gynecol Scand 1976;55:105-11
15. McBride WG. An aetiological study of drug ingestion by women who gave birth to babies with cleft palate. Austr N Zeal J Obstet Gynecol 1969;9:103-4
16. Milkovich L, van den Berg BJ. An evaluation of the teratogenicity of certain antinauseant drugs. Am J Obstetr Gynecol 1976;125:244-8
17. Shapiro S, Kaufman DW, Rosenberg L, et al. Meclizine in pregnancy in relation to congenital malformations. BMJ 1978;1:483
18. Yerushalmy J, Milkovich L. Evaluation of the teratogenic effect of meclizine in man. Am J Obstetr Gynecol 1965;93:553-62
19. Käll-en B, Mottet I. Delivery outcome after the use of meclozine in early pregnancy. Eur J Epidemiol 2003;18:665-9
20. Ashkenazi-Hoffnung L, Merlob P, Stahl B, Klinger G. Evaluation of the efficacy and safety of bi-daily combination therapy with pyridoxine and doxylamine for nausea and vomiting of pregnancy. Israel Med Assoc J 2013;15:23-6
21. Boskovic R, Rudic N, Danieliewska-Nikiel B, et al. Is lack of morning sickness teratogenic A prospective controlled study. Birth Defects Res A Clin Molec Teratol 2004;70:528-30
22. Einarson A, Bailey B, Jung G, et al. Prospective controlled study of hydroxyzine and cetirizine in pregnancy. Ann Allergy Asthma Immunol 1997;78:183-6
23. Erez S, Schifrin BS, Dirim O. Double-blind evaluation of hydroxyzine as an antiemetic in pregnancy. J Reprod Med 1971;7:35-27
24. Michaelis J, Michaelis H, Gluck E, Koller S. Prospective study of suspected associations between certain drugs administered during early pregnancy and congenital malformations. Teratology 1983;27:57-64
25. Aselton P, Jick H, Milunsky A, et al. First-trimester drug use and congenital disorders. Obstetr Gynecol 1985;65:451-5
26. Jick H, Holmes LB, Hunter JR, et al. First-trimester drug use and congenital disorders. JAMA 1981;246:343-6
27. Schatz M, Zeiger RS, Harden K, et al. The safety of asthma and allergy medications during pregnancy. J Allergy Clin Immunol 1997;100:301-6
28. Bsat FA, Hoffman DE, Seubert DE. Comparison of three outpatient regimens in the management of nausea and vomiting in pregnancy. J Perinatol 2003;23:531-5
29. Diav-Citrin O, Shechtman S, Aharonovich A, et al. Pregnancy outcome after gestational exposure to loratadine or antihistamines: A prospective controlled cohort study. J Allergy Clin Immunol 2003;111:1239-43
30. Käll-en B, Olausson PO. Monitoring of maternal drug use and infant congenital malformations. Does loratadine cause hypospadias Int J Risk Safety Med 2001;14:115-19
31. Käll-en B, Olausson PO. No increased risk of infant hypospadias after maternal use of loratadine in early pregnancy. Int J Med Sci 2006;3:106-7
32. Loebstein R, Lalkin A, Addis A, et al. Pregnancy outcome after gestational exposure to terfenadine: A multicenter, prospective controlled study. J Allergy Clin Immunol 1999;104:953-6
33. Moretti ME, Caprara D, Coutinho CJ, et al. Fetal safety of loratadine use in the first trimester of pregnancy: A multicenter study. J Allergy Clin Immunol 2003;111:479-83
34. Pastuszak A, Schick B, D'Alimonte D, et al. The safety of astemizole in pregnancy. J Allergy Clin Immunol 1996;98:748-50
35. Weber-Schoendorfer C, Schaefer C. The safety of cetirizine during pregnancy. A prospective observational cohort study. Reprod Toxicol 2008;26:19-23
36. Källen B, Robert-Gnansia E. Maternal drug use, fertility problems, and infant craniostenosis. Cleft Palate Craniofac J 2005;42:589-93
37. Werler MM, Mitchell AA, Shapiro S. First trimester maternal medication use in relation to gastroschisis. Teratology 1992;45:361-7
38. Werler MM, Sheehan JE, Mitchell AA. Maternal medication use and risks of gastroschisis and small intestinal atresia. Am J Epidemiol 2002;155:26-31
39. Boneva RS, Moore CA, Botto L, et al. Nausea during pregnancy and congenital heart defects: A population-based casecontrol study. Am J Epidemiol 1999;149:717-25
40. Aselton P, Jick H, Chentow SJ, et al. Pyloric stenosis and maternal Bendectin exposure. Am J Epidemiol 1984;120:251-6
41. Eskenazi B, Bracken MB. Bendectin (Debendox) as a risk factor for pyloric stenosis. Am J Obstetr Gynecol 1982;144:919-24
42. Aselton P, Jick H. Re: pyloric stenosis and maternal antihistamine exposure at group health cooperative. Am J Epidemiol 1985;122:197
43. Eskenazi B, Bracken MB. Pyloric stenosis and antihistamines. Am J Epidemiol 1985;122:196-7
44. Mellin GW, Katzenstein M. Meclozine and foetal abnormalities. Lancet 1963;1:222-3
45. Idanpaan-Heikkila J, Saxen L. Possible teratogenicity of imipramine-chloropyramine. Lancet 1973;2:282-4
46. Saxen I. Letter: cleft palate and maternal diphenhydramine intake. Lancet 1974;1:407-8
47. Golding J, Vivian S, Baldwin JA. Maternal anti-nauseants and clefts of lip and palate. Human Toxicol 1983;2:63-73
48. Nelson MM, Forfar JO. Associations between drugs administered during pregnancy and congenital abnormalities of the fetus. BMJ 1971;1:523-7
49. Czeizel AE, Vargha P. A case-control study of congenital abnormality and dimenhydrinate usage during pregnancy. Arch Gynecol Obstetr 2005;271:113-18
50. Bartfai Z, Kocsis J, Puho EH, Czeizel AE. A population-based casecontrol teratologic study of promethazine use during pregnancy. Reprod Toxicol 2008;25:276-85
51. Czeizel AE, Sarkozi A, Wyszynski DF. Protective effect of hyperemesis gravidarum for nonsyndromic oral clefts. Obstetr Gynecol 2003;101:737-44
52. Verberg MF, Gillott DJ, Al-Fardan N, Grudzinskas JG. Hyperemesis gravidarum, a literature review. Hum Reprod Update 2005;11:527-39
53. Anderka M, Mitchell AA, Louik C, et al. Medications used to treat nausea and vomiting of pregnancy and the risk of selected birth defects. Birth Defects Res A Clin Molec Teratol 2012;94:22-30
54. Li Q, Mitchell AA, Werler MM, et al. Assessment of antihistamine use in early pregnancy and birth defects. J Allergy Clin Immunol: In Practice 2013;1:666-74
55. Centers for Disease Control and Prevention. Evaluation of an association between loratadine and hypospadias-United States, 1997-2001. MMWR Morbidity and Mortality Weekly Report 2004;53:219-21
56. Pedersen L, Norgaard M, Rothman KJ, Sorensen HT. Loratadine during pregnancy and hypospadias. Epidemiology 2008;19:359-60
57. Pedersen L, Norgaard M, Skriver MV, et al. Prenatal exposure to loratadine in children with hypospadias: A nested casecontrol study within the Danish National Birth Cohort. Am J Therapeutics 2006;13:320-4
58. Pedersen L, Skriver MV, Norgaard M, Sorensen HT. Maternal use of loratadine during pregnancy and risk of hypospadias in offspring. Int J Med Sci 2006;3:21-5
59. Colin Jones DG, Langman MJ, Lawson DH, Vessey MP. Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report. Quarterly J Med 1985;54:253-68
60. Garbis H, Elefant E, Diav-Citrin O, et al. Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services. Reprod Toxicol 2005;19:453-8
61. Källen B. Delivery outcome after the use of acid-suppressing drugs in early pregnancy with special reference to omeprazole. Br J Obstetr Gynecol 1998;105:877-81
62. Magee LA, Inocencion G, Kamboj L, et al. Safety of first trimester exposure to histamine H2 blockers. A prospective cohort study. Dig Dis Sci 1996;41:1145-9
63. Matok I, Gorodischer R, Koren G, et al. The safety of H(2)-blockers use during pregnancy. J Clin Pharmacol 2010;50:81-7
64. Ruigomez A, Garcia Rodriguez LA, Cattaruzzi C, et al. Use of cimetidine, omeprazole, and ranitidine in pregnant women and pregnancy outcomes. Am J Epidemiol 1999;150:476-81
65. Lalkin A, Loebstein R, Addis A, et al. The safety of omeprazole during pregnancy: A multicenter prospective controlled study. Am J Obstetr Gynecol 1998;179:727-30
66. Á cs N, Bánhidy F, Puho EH, Czeizel AE. A possible association between maternal dyspepsia and congenital rectal/anal atresia/stenosis in their children: A population-based casecontrol study. Acta Obstetr Gynecol Scand 2009;88:1017-23
67. Bánhidy F, Dakhlaoui A, Puho EH, Czeizel AE. Peptic ulcer disease with related drug treatment in pregnant women and congenital abnormalities in their offspring. Congen Anomal 2011;51:26-33
68. Centers for Disease Control and Prevention. Update on overall prevalence of major birth defects-Atlanta, Georgia, 1978-2005. MMWR Morbidity and Mortality Weekly Report 2008;57:1-5
69. Shapiro S, Heinonen OP, Siskind V, et al. Antenatal exposure to doxylamine succinate and dicyclomine hydrochloride (Benedectin) in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstetr Gynecol 1977;128:480-5
70. Hardy JB. The Collaborative Perinatal Project: lessons and legacy. Ann Epidemiol 2003;13:303-11
71. Klebanoff MA. The Collaborative Perinatal Project: A 50-year retrospective. Paediatr Perinatal Epidemiol 2009;23:2-8
72. Honein MA, Moore CA. The safety or risk of antihistamine use in pregnancy: reassuring data are helpful but not sufficient. J Allergy Clin Immunol: In Practice 2013;1:675-6
73. Olesen C, Sondergaard C, Thrane N, et al. Do pregnant women report use of dispensed medications Epidemiology 2001;12:497-501
74. Werler MM, Pober BR, Nelson K, Holmes LB. Reporting accuracy among mothers of malformed and nonmalformed infants. Am J Epidemiol 1989;129:415-21
75. Cogswell ME, Bitsko RH, Anderka M, et al. National Birth Defects Prevention Study. Control selection and participation in an ongoing, populationbased, case-control study of birth defects: the National Birth Defects Prevention Study. Am J Epidemiol 2009;170:975-85
76. Sadler TW. Langman's Medical Embryology. 8th Edition. Lippincott Williams & Wilkins; Philadelphia: 2004
77. Yau WP, Lin KJ, Werler MM, et al. Drug certainty-response in interviewbased studies. Pharmacoepidemiol Drug Saf 2011;20:1210-16
78. Psaty BM, Koepsell TD, Lin D, et al. Assessment and control for confounding by indication in observational studies. J Am Geriatrics Soc 1999;47:749-54
79. Mitchell AA, Gilboa SM, Werler MM, National Birth Defects Prevention Study. Medication use during pregnancy, with particular focus on prescription drugs: 1976-2008. Am J Obstet Gynecol 2011;205:51.e1-8
80. Botto LD, Lin AE, Riehle-Colarusso T, et al. Seeking causes: classifying and evaluating congenital heart defects in etiologic studies. Birth Defects Res A Clin Molec Teratol 2007;79:714-27
81. Rasmussen SA, Olney RS, Holmes LB, et al. Guidelines for case classification for the National Birth Defects Prevention Study. Birth Defects Res A Clin Molec Teratol 2003;67:193-201
82. Riehle-Colarusso T, Strickland MJ, Reller MD, et al. Improving the quality of surveillance data on congenital heart defects in the metropolitan Atlanta congenital defects program. Birth Defects Res A Clin Molec Teratol 2007;79:743-53